Personalized precision medicine is the focus of a scientific conference organized by the ibs.GRANADA
The conference has addressed the main advances in precision medicine research by numerous multidisciplinary research groups in Granada.
The Granada Biosanitary Research Institute (ibs.GRANADA) successfully held its fifth Precision Medicine Conference at the Faculty of Medicine of the University of Granada. The event, which brought together leading experts from the healthcare, research and academic fields, focused on the Latest advances in the use of innovative technologies for the prevention, diagnosis and personalized treatment of various pathologies.
The opening of the day was attended by key authorities from Granada, Dr. Manuel Reyes Nadal, managing director of the San Cecilio University Clinical Hospital; Dr. María Ángeles García Rescalvo, managing director of the Virgen de las Nieves University Hospital; and Dr. María José Sánchez Pérez, scientific director of the ibs.GRANADA.
Dr. Juan Jiménez Jáimez and Dr. Beatriz García Fontana, coordinators of the Precision Medicine Area of the ibs.GRANADA, presented the program of the conference, highlighting the importance of precision medicine in the advancement of biomedical research.
One of the most anticipated moments was the inaugural lecture given by Professor César de la Fuente, from the University of Pennsylvania, entitled "Artificial Intelligence for antibiotic discoveryHis presentation explored how new technologies are revolutionizing drug discovery, opening up new avenues for combating drug-resistant infections.
The event was organised into two thematic sessions on Precision Medicine and a presentation of scientific posters, which addressed cutting-edge research in intestinal microbiota, otoneurology, cardiovascular diseases and autoimmune diseases. The speakers presented key advances in the modulation of inflammation, the control of vascular damage and the treatment of pain. After a break to facilitate interaction between attendees, the second session continued with presentations on urological oncology, child nutrition and neurodegenerative diseases, highlighting topics such as the bone-vascular connection, biomarkers in thyroid ophthalmopathy and lysosomal dysfunction in Parkinson's.
Dr. Paloma Muñoz de Rueda presented the Scientific-Technological Platforms of the ibs.GRANADA, highlighting the resources available to researchers to enhance their studies in precision medicine. In addition, selected oral communications were given, addressing advances such as the identification of a new genetic subtype associated with a high risk of sudden death, gene therapy strategies for mitochondrial encephalopathies and the association between overweight/obesity during pregnancy and behavioural problems in children.
One of the highlights of the event was the closing conference entitled "Nanotechnology at the service of Precision Medicine: Revolutionizing the Biomedicine of the Future", led by Professor María Vallet Regí, professor emeritus at the Complutense University of Madrid. Professor Vallet explained how nanotechnology is transforming personalized medicine, offering more precise and effective treatments.
The event concluded with the presentation of awards for the best scientific communications and the participation of patient associations who shared their testimonies.
The event was a resounding success, consolidating the ibs.GRANADA as a benchmark in Precision Medicine research at national and international level.
About the ibs.GRANADA
The Instituto de Investigación Biosanitaria ibs.GRANADA, is the only center accredited by the Carlos III Health Institute (ISCIII) that develops biomedical research of excellence in Granada and one of the four accredited in Andalusia by the ISCIII.
The ibs.GRANADA is structured in four Scientific Areas: Oncology, Precision Medicine, Epidemiology and Public Health and Technology and Advanced Therapies that develop an intense research activity and lead the transfer of research results to society, which are reflected in the 1.210 publications made in scientific journals, totaling 6.668 impact factor points, as well as 19 patents applied for during 2023.
Currently, the Institute brings together 1.088 professionals and 69 multidisciplinary research groups that comprise, from the University of Granada, the Virgen de las Nieves University Hospital, the San Cecilio Clinical University Hospital, the Andalusian School of Public Health and the centers of Primary Care of Granada.
The main objectives of ibs.GRANADA are to promote biomedical, clinical and epidemiological research carried out by the different groups attached to the institute and to facilitate translational research in Granada hospitals. This research activity translates into the generation of knowledge and the transfer of scientific advances towards the prevention, diagnosis and treatment of priority health problems in Andalusia.
